Stock 6998 GENOR BIOPHARMA HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genor Biopharma Holdings Limited

Equities

6998

KYG3871A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:03 23/05/2024 pm IST 		5-day change 1st Jan Change
1.4 HKD -4.11% Intraday chart for Genor Biopharma Holdings Limited +0.72% +17.65%
27/03 Genor Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
14/03 China's Drug Regulator Accepts Genor Biopharma's New Breast Cancer Drug Application; Shares Up 7% MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 8,266 2,895 1,172 544.8
Enterprise Value (EV) 1 5,367 752.1 -387.7 -613.5
P/E ratio -1.36 x -3.28 x -1.62 x -0.81 x
Yield - - - -
Capitalization / Revenue 800 x - 73.6 x -
EV / Revenue 519 x - -24.3 x -
EV / EBITDA -5.82 x -0.9 x 0.52 x 1.11 x
EV / FCF -91,96,255 x -18,68,331 x 10,44,027 x 27,82,175 x
FCF Yield -0% -0% 0% 0%
Price to Book 2.55 x 1.15 x 0.65 x 0.46 x
Nbr of stocks (in thousands) 4,91,030 5,00,474 4,99,058 5,03,733
Reference price 2 16.83 5.785 2.349 1.082
Announcement Date 27/04/21 28/04/22 28/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 6.882 13.04 10.33 - 15.93 -
EBITDA 1 -265.2 -493.7 -921.9 -840.2 -748.6 -551
EBIT 1 -293.2 -524.6 -958.4 -884.2 -785.2 -616.3
Operating Margin -4,260.93% -4,023.03% -9,276.55% - -4,928.55% -
Earnings before Tax (EBT) 1 -288.1 -523.6 -3,036 -866.3 -732.4 -677.5
Net income 1 -288.1 -522.1 -3,027 -865.2 -730.2 -674.4
Net margin -4,185.95% -4,004% -29,301.15% - -4,583.32% -
EPS 2 -1.122 -1.888 -12.36 -1.766 -1.448 -1.332
Free Cash Flow - 511.2 -583.6 -402.5 -371.4 -220.5
FCF margin - 3,920.79% -5,648.94% - -2,330.85% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 30/06/20 30/06/20 27/04/21 28/04/22 28/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2
Net sales 1 3.76 6.57 - - 2.956 12.98
EBITDA - - - - - -
EBIT 1 - - -416.1 -502.6 -440.1 -346.1
Operating Margin - - - - -14,887.79% -2,667.4%
Earnings before Tax (EBT) - - - - - -
Net income - - - - -405.6 -
Net margin - - - - -13,722.29% -
EPS 2 - - -0.8200 -0.9300 -0.8100 -0.6400
Dividend per Share - - - - - -
Announcement Date 27/09/21 23/03/21 26/08/21 30/03/22 30/08/22 30/03/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 80.4 212 2,899 2,143 1,560 1,158
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 511 -584 -403 -371 -221
ROE (net income / shareholders' equity) - -99.7% -175% -30.2% -34% -45.1%
ROA (Net income/ Total Assets) - -38.1% -27.8% -17.2% -19.7% -21.6%
Assets 1 - 1,370 10,882 5,039 3,703 3,118
Book Value Per Share 2 3.210 0.7900 6.610 5.020 3.590 2.360
Cash Flow per Share 2 0.4900 0.9200 5.990 4.440 3.170 2.310
Capex 1 27.6 20.6 28.3 46.5 9.04 1.03
Capex / Sales 401.58% 157.93% 274.1% - 56.74% -
Announcement Date 30/06/20 30/06/20 27/04/21 28/04/22 28/04/23 25/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENOR BIOPHARMA HOLDINGS LIMITED Stock Genor Biopharma Holdings Limited
+17.65% 9.52Cr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+10.79% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.65% 11TCr
BIONTECH SE Stock BioNTech SE
-6.20% 2.47TCr
ARGENX SE Stock argenx SE
-2.33% 2.2TCr
GENMAB A/S Stock Genmab A/S
-6.03% 1.93TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.41% 1.76TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.50% 1.73TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.64% 1.4TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.84% 1.21TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6998 Stock
  4. Financials Genor Biopharma Holdings Limited